

## ASHP Alopecia Symposium Pretest/Posttest Questions

Which of the following do patients with AA identify as being the most significantly impacted by their hair loss?

- a) Attendance at work/school
- b) Interpersonal relationships
- c) Self-confidence

**Rationale:** According to a 2020 US survey by Mesinkovska et al., patients with AA report substantial effects of hair loss across many clinical domains, with the greatest impact being on self-esteem and self-confidence.

**Reference:**

Mesinkovska N, et al. *J Investig Dermatol Symp Proc.* 2020;20:S62-S68.

JAK inhibitor treatment is associated with achievement of  $\leq 20\%$  scalp hair loss (SALT  $\leq 20\%$ ) in approximately what percentage of patients with alopecia areata?

- a)  $<20\%$
- b) 20 to 30%
- c) 30 to 40%

**Rationale:** Following daily treatment with 4-mg baricitinib, the percentage of patients with SALT  $\leq 20\%$  at week 36 was 38.8% in BRAVE-AA1 and 35.9%, in BRAVE-AA2.

**References:** King B, et al. *New Engl J Med.* 2022;386:1687-1699; King B. Presented at the 30th Congress of the EADV. 2021.

Kaleigh is a 23-year-old woman with severe AA who began treatment with a JAK inhibitor 6 weeks ago and has requested a prescription refill. At the time of her request, she mentions that she has had persistent cold symptoms (nasopharyngitis) over the last 2 weeks. Which of the following would you do prior to completing the refill?

- a) Inform the patient that nasopharyngitis is a common side effect of the medication
- b) Advise the patient that cold symptoms are unlikely to be related to the medication and recommend OTC treatment for cold symptoms
- c) Advise the patient to stop taking the medication immediately

**Rationale:** It is important to help patients identify common side effects of JAK inhibitor treatment (such as nasopharyngitis) vs those that are more serious.

**Reference:** Olumiant [package insert]. Indianapolis, IN, USA; Lilly USA, LLC; Revised 2022. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/207924s006lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207924s006lbl.pdf)

The potential place of emerging therapies for AA will be influenced by their potential to positively impact the cost of AA care over the long-term. How do current healthcare utilization costs among patients with AA compare with patients who do not have AA?

- a) No significant difference in costs
- b) 15% greater costs
- c) 35% greater costs

**Rationale/Reference:** According to a 2022 retrospective analysis among US patients with AA by Mostaghimi et al., total all-cause healthcare utilization costs in patients with AA vs those without were \$8557 (\$7679–\$9535) vs \$6314 (\$4455–\$8947), respectively.